An announcement from Xenon ( (XENE) ) is now available.
Xenon Pharmaceuticals Inc. announced its participation in the 45th Annual TD Cowen Healthcare Conference, where key executives will present. This event represents an opportunity for Xenon to showcase its advancements and engage with stakeholders, potentially impacting its market presence and investor relations.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Their most advanced product, Azetukalner, is a novel, highly potent, selective Kv7 potassium channel opener in late-stage clinical development for multiple indications.
YTD Price Performance: -4.48%
Average Trading Volume: 406,247
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.93B
See more data about XENE stock on TipRanks’ Stock Analysis page.